<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03356236</url>
  </required_header>
  <id_info>
    <org_study_id>HE-201708</org_study_id>
    <nct_id>NCT03356236</nct_id>
  </id_info>
  <brief_title>Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation</brief_title>
  <official_title>A Multicenter, Prospective Cohort Study Investigating Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yue Han</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of Huaier Granule for Prevention of Recurrence and&#xD;
      Metastasis of Hepatocarcinoma following Local Ablation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter, prospective cohort study investigating Huaier Granule for Prevention of&#xD;
      Recurrence and Metastasis of Hepatocarcinoma following Local Ablation，to evaluate the&#xD;
      efficacy and safety&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>96 weeks</time_frame>
    <description>PFS was defined as the duration of time from start of treatment to time of disease progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence-Free Survival (RFS)</measure>
    <time_frame>96 weeks</time_frame>
    <description>RFS was defined as the duration of time from start of treatment to time of disease recurrence .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence (TTR)</measure>
    <time_frame>Time from baseline to relapse (up to 96 weeks)</time_frame>
    <description>TTR was defined as the time from shart of treatment to disease recurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Time from baseline to death (up to 96 weeks)</time_frame>
    <description>OS was defined as the time from start to death from any cause or last patient last visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life (QOL)</measure>
    <time_frame>24, 48, 72, 96 weeks</time_frame>
    <description>Quality of Life (QOL) were measured using supplemental quality of life questions. Item score range（12 items）: 1 (worst symptom) to 5 (no symptom). Change: score at 96 weeks minus score at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of Adverse events (AE)</measure>
    <time_frame>96 weeks</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>severity of Adverse events (AE)</measure>
    <time_frame>96 weeks</time_frame>
    <description>An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">828</enrollment>
  <condition>Hepatocarcinoma</condition>
  <arm_group>
    <arm_group_label>Observation group 1</arm_group_label>
    <description>All treatments of patients after Local Ablation are prescribed by a physician on the basis of usual clinical practice.Patients who maybe receive Huaier Granule are as observation group 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation group 2</arm_group_label>
    <description>All treatments of patients after Local Ablation are prescribed by a physician on the basis of usual clinical practice.Patients who maybe not receive Huaier Granule are as observation group 2</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Hepatocellular Carcinoma patients after Local Ablation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years ≤ Age ≤ 75 years, both male and female&#xD;
&#xD;
          2. Patients are diagnosed with HCC via examination of tissues according to Guidelines for&#xD;
             Diagnosis and Treatment of Hepatocellular Carcinoma (Version 2017) by NHFPC (National&#xD;
             Health and Family Planning Commission of the People's Republic of China) and/or HCC&#xD;
             imaging criteria of American Association for the Study of Liver Diseases (AASLD) for&#xD;
             the diagnosis of HCC;&#xD;
&#xD;
          3. Radiographic testing shows cancer cells have been eliminated after four weeks of Local&#xD;
             Ablation;Complete Response (CR): Dynamic contrast-enhanced CT scans and follow-up MR&#xD;
             images show low-density area of Hepatocellular Carcinoma and no enhancement during the&#xD;
             arterial phase of contrast-enhanced CT; also patients with 0.5-1 cm beyond the limits&#xD;
             of the tumor margins (considered as safe surgical margins) are eligible;&#xD;
&#xD;
          4. According to contrast-enhanced CT and MRI, with solitary tumor smaller than 5 cm in&#xD;
             diameter; with multiple tumors (no more than 3 masses), the largest dimension is less&#xD;
             than 3 cm;&#xD;
&#xD;
          5. Patients are eligible if Hemoglobin (Hb) count ≥90g/L, platelets count (PLT)&#xD;
             ≥60×109/L, absolute neutrophil count (ANC) count &gt;1.0×109/L, prothrombin activity&#xD;
             (PTA)&gt;50%, serum creatinine is less than 1.5 times ULN (Upper Limit of Normal) and&#xD;
             total bilirubin (TBIL) &lt;51.3μmol/L (3 mg/dL);&#xD;
&#xD;
          6. ECOG score of 0-1;&#xD;
&#xD;
          7. Liver function is Child - Pugh grade A or B.&#xD;
&#xD;
          8. History of TACE for treatment of HCC is less than or equal to twice -&#xD;
&#xD;
          9. The patients are volunteered for the study, sign informed consent form and cooperate&#xD;
             with Investigator to collect data.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Radiographic testing shows cancer cells have not been eliminated after four weeks of&#xD;
             Local Ablation;&#xD;
&#xD;
          2. The occurrence of embolism occurs in large blood vessels on liver, patients with&#xD;
             extrahepatic metastatic of HCC or liver transplantation;&#xD;
&#xD;
          3. Patients who are about to receive or already received chemotherapy or molecular&#xD;
             targeted therapy;&#xD;
&#xD;
          4. Patients who are about to receive TACE treatment for HCC;&#xD;
&#xD;
          5. Patients without previous treatment of Huaier granules.&#xD;
&#xD;
          6. History of diabetes;&#xD;
&#xD;
          7. HCC patients with uncontrollable ascites at the beginning of enrollment of the study&#xD;
             or are very likely to have ascites during the next four weeks at the time of&#xD;
             enrollment; patients with hepatic encephalopathy or upper gastrointestinal bleeding;&#xD;
&#xD;
          8. Patients have basic diseases including severe cardiopulmonary insufficiency, renal&#xD;
             insufficiency, or severe mental illness;&#xD;
&#xD;
          9. Patients with other infectious disease (excluding viral hepatitis)&#xD;
&#xD;
         10. Patients who cannot take oral medication;&#xD;
&#xD;
         11. Conditions that are considered not suitable for this study investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yue Han, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yue Han, Professor</last_name>
    <phone>+0086-13511021629</phone>
    <email>doctorhan001@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Han</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiaping Li</last_name>
      <phone>+86-13352890908</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shijiazhuang Fifth Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huanwei Zheng</last_name>
      <phone>+86-13323119317</phone>
      <email>13323119317@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Cancer Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruibao Liu</last_name>
      <phone>+86-13936586155</phone>
      <email>ruibaoliu@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hailaing Li</last_name>
      <phone>+86-13903861969</phone>
      <email>cjr.lihailiang@vip.163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chidan Wan</last_name>
      <phone>+86-13871289836</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Zhongshan Hospital of Dalian University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Zhou</last_name>
      <phone>+86-18698629436</phone>
      <email>zhoujun7092@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Song</last_name>
      <phone>+86-17709876600</phone>
      <email>songlei_1975@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Ye</last_name>
      <phone>+86-15168887755</phone>
      <email>yexintaian@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuliang Li</last_name>
      <phone>+86-13573780666</phone>
      <email>lyl.pro@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zixiang Li</last_name>
      <phone>+86-18669739263</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Xu</last_name>
      <phone>+86-13700222215</phone>
      <email>xujun1964@xjtufh.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>the Second Affiliated Hospital Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhe Tang, professor</last_name>
      <phone>+86-13757118212</phone>
      <email>dicktang@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing You 'an Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiasheng Zheng</last_name>
      <phone>+86-13901355160‬</phone>
      <email>13901355160@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yue Han</last_name>
      <phone>+86-13511021629</phone>
      <email>doctorhan@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Chongqing Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingdong Li</last_name>
      <phone>+86-13650582046</phone>
      <email>xj2010045@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Zhai</last_name>
      <phone>+86-13918656019</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 12, 2017</study_first_submitted>
  <study_first_submitted_qc>November 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2017</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Yue Han</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

